Department of Urology, Medical Faculty, Inonu University, Malatya, Turkey.
Ren Fail. 2012;34(3):343-9. doi: 10.3109/0886022X.2011.647305. Epub 2012 Jan 20.
In this study, the therapeutic and protective effects of montelukast against cisplatin (CP)-induced acute renal damage were investigated.
Thirty-five female rats were divided into five groups as follows: (1) control, (2) montelukast (10 mg/kg daily for 10 days per-oral (p.o.), (3) CP (single dose 7 mg/kg intraperitoneally (i.p.)), (4) CP + montelukast (10 mg/kg daily for 10 days p.o., after 3 days of the injection of CP), (5) montelukast (10 mg/kg daily for 10 days p.o.) + CP (single dose 7 mg/kg i.p., after the last dose of montelukast). At the end of the experiment, malondialdehyde (MDA), a lipid peroxidation product, myeloperoxidase (MPO), and reduced glutathione (GSH) levels were determined in the renal tissue. Also, blood urea nitrogen (BUN) and creatinine (Cr) levels were assayed from the trunk blood samples.
CP treatment caused a significant elevation of MDA, MPO, BUN, and Cr levels when compared with the control group. Also, GSH levels were found to be reduced due to the CP treatment. Montelukast administration after CP injection ameliorated all of these parameters. Our histopathological findings (marked swelling of epithelial cells, tubular dilatation, tubular desquamation, and loss of brush border in the kidney) were consistent with the biochemical results.
Montelukast treatment after CP injection exerted therapeutic effects against CP-induced acute kidney damage.
本研究旨在探讨孟鲁司特（montelukast）对顺铂（CP）诱导的急性肾损伤的治疗和保护作用。
35 只雌性大鼠被分为五组：（1）对照组；（2）孟鲁司特组（10mg/kg，每日口服，共 10 天）；（3）CP 组（单次腹腔注射 7mg/kg）；（4）CP+孟鲁司特组（CP 注射 3 天后，开始每日口服 10mg/kg 孟鲁司特，共 10 天）；（5）孟鲁司特组（10mg/kg，每日口服，共 10 天）+CP 组（最后一次孟鲁司特给药后，单次腹腔注射 7mg/kg CP）。实验结束时，测定肾组织中丙二醛（MDA）、髓过氧化物酶（MPO）和还原型谷胱甘肽（GSH）的水平，并从大鼠的 trunk blood 样本中检测血尿素氮（BUN）和肌酐（Cr）的水平。
与对照组相比，CP 处理导致 MDA、MPO、BUN 和 Cr 水平显著升高，同时 GSH 水平降低。CP 注射后给予孟鲁司特治疗可改善所有这些参数。我们的组织病理学发现（上皮细胞明显肿胀、肾小管扩张、肾小管脱落和刷状缘丧失）与生化结果一致。
CP 注射后给予孟鲁司特治疗对 CP 诱导的急性肾损伤具有治疗作用。
